Casi pharmaceuticals qtrly loss per share $0.10

Casi pharmaceuticals announces third quarter 2019 financial results.casi pharmaceuticals inc - revenue from evomela was $2.7 million for q3 2019.casi pharmaceuticals inc - qtrly loss per share $0.10.

CASI Ratings Summary

CASI Quant Ranking